I-MAB

Q: What was I-MAB’s price range in the past 12 months?

I-MAB lowest stock price was $0.59 and its highest was $6.79 in the past 12 months.

Q: What is I-MAB’s market cap?

I-MAB’s market cap is $367.45M.

Q: When is I-MAB’s upcoming earnings report date?

I-MAB’s upcoming earnings report date is Nov 13, 2025 which is in 13 days.

Q: How were I-MAB’s earnings last quarter?

I-MAB released its earnings results on Aug 20, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.054 by $0.024.

Q: Is I-MAB overvalued?

According to Wall Street analysts I-MAB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does I-MAB pay dividends?

I-MAB does not currently pay dividends.

Q: What is I-MAB’s EPS estimate?

I-MAB’s EPS estimate is -0.04.

Q: How many shares outstanding does I-MAB have?

I-MAB has 115,119,490 shares outstanding.

Q: What happened to I-MAB’s price movement after its last earnings report?

I-MAB reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.054. Following the earnings report the stock price went up 7.363%.

Q: Which hedge fund is a major shareholder of I-MAB?

Currently, no hedge funds are holding shares in IMAB

Compare

418 Followers

IMAB Stock Chart & Stats

$4.64

$0.18(18.08%)

At close: Jan 08 4:00 PM EST

$4.64

$0.18(18.08%)

Day’s Range― - ―

52-Week Range$0.60 - $6.79

Previous CloseN/A

Volume876.01K

Average Volume (3M)1.83M

Market Cap

$367.45M

Enterprise Value$35.53M

Total Cash (Recent Filing)$165.61M

Total Debt (Recent Filing)$3.48M

Price to Earnings (P/E)―

Beta1.63

Next Earnings

Nov 13, 2025

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding115,119,490

10 Day Avg. Volume1,836,982

30 Day Avg. Volume1,828,561

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.34

Price to Sales (P/S)0.00

P/FCF Ratio-1.31

Enterprise Value/Market Cap0.10

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.96

Forecast

1Y Price Target

$8.25

Price Target Upside77.80% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentsI-Mab reported positive updated Phase 1 monotherapy results for givastomig, reinforcing the asset’s best in class profile in metastatic gastric cancer.

Global ExpansionI-Mab is accelerating development with a global randomized Phase 2 initiation and topline Ph1b expansion data release, creating near-term catalysts.

Market OpportunitiesGivastomig's design effectively doubles the addressable market by driving activity across CLDN18.2-low and PD-L1-low populations.

Bears Say

Corporate HistoryI-Mab has a history of corporate resets and program discontinuations or divestitures.

Market MisinterpretationI-Mab shares fell ~20% following a New York Times article, seen as an unwarranted mispricing due to the mischaracterization of I-Mab as a Chinese drugmaker.

Strategic UncertaintyThe strategic transformation introduces incremental uncertainty around capital allocation timing and governance focus.

I-MAB News

One new option listing and two option delistings on October 30th

New option listings for October 30th include I-MAB American Depositary Shares (NBP). Option delistings effective October 30th include...

18h ago

HON

IMAB

I-Mab changes corporate name to NovaBridge Biosciences

NovaBridge (NBP) Biosciences has changed its corporate name from I-Mab (IMAB) to NovaBridge Biosciences. The change was overwhelmingly...

2d ago

IMAB

Midday Fly By: Apple new F1 broadcast partner, CSX reports Q3 beat

The major averages were higher near noon as the U.S. government shutdown enters its seventeenth day with no...

14d ago

I MAB (ADS) trading resumes

16:25 EDT I MAB (ADS) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

14d ago

IMAB

I-Mab intends to pursue Hong Kong IPO, rebrand as NovaBridge Biosciences

I-Mab (IMAB) announced its new business model, focused on its global capabilities built to accelerate access to medicines...

14d ago

IMAB

I-Mab names Kyler Lei as CFO, announces pending acquisition of VIS-101

The company also announced the pending acquisition of VIS-101, a novel bifunctional biologic targeting VEGF-A and ANG2. The...

14d ago

IMAB

I MAB (ADS) trading halted, news pending

16:01 EDT I MAB (ADS) trading halted, news pending Published first on TheFly – the ultimate source for...

14d ago

IMAB

I-Mab initiated with an Outperform at Leerink

Leerink analyst Daina M. Graybosch initiated coverage of I-Mab (IMAB) with an Outperform rating and $9 price target...

28d ago

IMAB

NovaBridge Subsidiary Assigns VIS-101 License to Everest Medicines

An announcement from I-MAB ( ($IMAB) ) is now available. On October 28, 2025, NovaBridge Biosciences’ subsidiary, Visara,...

20h ago

IMAB

NovaBridge Biosciences Unveils New Identity and Strategic Direction

I-MAB ( ($IMAB) ) just unveiled an update. On October 24, 2025, shareholders of I-MAB approved a name...

1d ago

IMAB

I-MAB Completes Acquisition of Bridge Health Biotech

I-MAB ( ($IMAB) ) has issued an announcement. On October 28, 2025, I-MAB announced the completion of its...

2d ago

IMAB

Promising Clinical Data and Strategic Uncertainties: Analyst Recommends ‘Buy’ for I-MAB

H.C. Wainwright analyst Andres Y. Maldonado has maintained their bullish stance on IMAB stock, giving a Buy rating...

4d ago

IMAB

I-Mab Rebrands to NovaBridge Biosciences Following Shareholder Approval

An update from I-MAB ( ($IMAB) ) is now available. On October 24, 2025, I-Mab held an extraordinary...

6d ago

IMAB

I-MAB Releases Promising Phase I Data for Givastomig in Advanced Gastric Cancer

I-MAB ( ($IMAB) ) just unveiled an announcement. I-MAB has released updated data from its Phase I study...

7d ago

IMAB

IMAB FAQ

What was I-MAB’s price range in the past 12 months?

I-MAB lowest stock price was $0.59 and its highest was $6.79 in the past 12 months.

What is I-MAB’s market cap?

I-MAB’s market cap is $367.45M.

When is I-MAB’s upcoming earnings report date?

I-MAB’s upcoming earnings report date is Nov 13, 2025 which is in 13 days.

How were I-MAB’s earnings last quarter?

I-MAB released its earnings results on Aug 20, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.054 by $0.024.

Is I-MAB overvalued?

According to Wall Street analysts I-MAB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does I-MAB pay dividends?

I-MAB does not currently pay dividends.

What is I-MAB’s EPS estimate?

I-MAB’s EPS estimate is -0.04.

How many shares outstanding does I-MAB have?

I-MAB has 115,119,490 shares outstanding.

What happened to I-MAB’s price movement after its last earnings report?

I-MAB reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.054. Following the earnings report the stock price went up 7.363%.

Which hedge fund is a major shareholder of I-MAB?

Currently, no hedge funds are holding shares in IMAB

I-MAB Stock Smart Score

Outperform

Company Description

I-MAB

I-MAB (IMAB) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The company is engaged in the development of innovative monoclonal antibodies and biologics, leveraging its integrated research and development capabilities. I-MAB aims to address unmet medical needs through its proprietary drug discovery and development platforms.

I-MAB (IMAB) Earnings & Revenues

Historic Earnings Reports

IMAB Stock 12 Month Forecast

Average Price Target

$8.25

▲(77.80% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","-1":"-$1","1.75":"$1.75","4.5":"$4.5","7.25":"$7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.86,4.2553846153846155,4.650769230769231,5.046153846153846,5.441538461538462,5.836923076923077,6.2323076923076925,6.627692307692309,7.023076923076923,7.418461538461539,7.813846153846154,8.20923076923077,8.604615384615386,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.86,4.197692307692307,4.535384615384615,4.873076923076923,5.21076923076923,5.548461538461538,5.886153846153846,6.223846153846154,6.561538461538461,6.899230769230769,7.236923076923077,7.5746153846153845,7.912307692307692,{"y":8.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.86,4.101538461538461,4.343076923076923,4.584615384615384,4.826153846153846,5.067692307692307,5.309230769230769,5.55076923076923,5.792307692307692,6.033846153846154,6.275384615384615,6.516923076923076,6.758461538461539,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.81,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.85,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.86,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >